Abstract 128P
Background
Uveal melanoma is a rare disease, with limited treatment options in the metastatic setting. The objective of this study was to assess the effect of an online continuous medical education (CME) activity on oncologists’ knowledge and confidence in understanding uveal melanoma and the latest treatment developments.
Methods
This CME activity consisted of a 30-minute video discussion between 2 expert faculty with synchronised slides. Effectiveness of this education was assessed with a repeated-pairs pre-/post-assessment study design using 3 knowledge questions and 1 confidence question, in which each individual served as their own control. A paired samples t-test assessed mean differences in average number of correct responses pre- to post-assessment, and a McNemar’s test assessed significant improvement at question level. P values <.05 are statistically significant. The activity launched on Jun 21, 2021, with data collected through to Nov 1, 2021.
Results
86 oncologists who answered all the assessment questions were included in this analysis. There was a significant increase from 35% pre to 62% post-education (P<.001) in the average knowledge of oncologists as assessed by correct responses to the knowledge questions. There was a statistically significant improvement in knowledge in the following areas as shown in the table. There was a measurable improvement in confidence in around 45% of oncologists regarding understanding of the latest clinical trial data, and an increase from 12% pre-education to 27% post-education of oncologists being mostly or very confident. Table: 128P
| Pre-activity correct responses | Post-activity correct responses | P-value | |
| The different biological behaviour between cutaneous and uveal melanoma | 33% | 70% | <.001 |
| Current guideline recommendations for the treatment of metastatic uveal melanoma | 50% | 62% | <.05 |
| The latest clinical trial data investigating immunotherapies for the treatment of metastatic uveal melanoma | 22% | 55% | <.001 |
Conclusions
This analysis demonstrates the positive educational impact of an online CME activity on the latest developments in the treatment of uveal melanoma. As new data emerges and guidelines are updated, it will be important to educate clinicians on these developments so that they feel confident and competent when applying them in their clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medscape.
Funding
The educational activity was supported by an independent educational grant from Immunocore.
Disclosure
P. Nathan: Financial Interests, Personal, Advisory Board: BMS, Immunocore, Novartis, Merck, Pfizer, 4SC; Financial Interests, Institutional, Other, research support: Immunocore; Financial Interests, Personal, Invited Speaker: Novartis, 4SC; Financial Interests, Institutional, Invited Speaker: BMS, Novartis, Ipsen, Immunocore, Merck, Pfizer. R.D. Carvajal: Financial Interests, Personal, Other, Consulting: Alkermes, BMS, Castle Biosciences, Delcath, Eisai, Hengrui, Ideaya, Immunocore, InxMed, Iovance, Merck, Novartis, Oncosec, Pierre Fabre, PureTech Health, Regeneron, Sanofi Genzyme, Sorrento Therapeutics, Trisalus; Financial Interests, Personal, Advisory Board: Aura Biosciences, Chimeron, Rgenix; Financial Interests, Institutional, Research Grant: Amgen, Astellis, AstraZeneca, BMS, Bristol Myers Squibb, Corvus, Ideaya, Immunocore, Iovnce, Merck, Mirati, Novartis, Pfizer, Plexxikon, Regeneron, Roche/Genentech. All other authors have declared no conflicts of interest.